t failure is a major public health problem and an expensive one due to repeat hospitalizations since patients??? worsening symptoms keep coming back.??? ???Our findings suggest serelaxin holds promise as the first evidence-based therapy for acute heart failure to substantially improve patients??? symptoms and clinical outcomes, including death,??? said Teerlink, who is director of the heart failur